These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28008986)

  • 1. Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodeling.
    Zhao CZ; Zhao XM; Yang J; Mou Y; Chen B; Wu HD; Dai DP; Ding J; Hu SJ
    Sci Rep; 2016 Dec; 6():39186. PubMed ID: 28008986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice.
    Yang J; Mou Y; Wu T; Ye Y; Jiang JC; Zhao CZ; Zhu HH; Du CQ; Zhou L; Hu SJ
    Cardiovasc Res; 2013 Mar; 97(3):490-9. PubMed ID: 23180723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.
    Chen B; Zhong LY; Yang JX; Pan YY; Chen F; Yang J; Wu T; Hu SJ
    Cell Physiol Biochem; 2013; 32(6):1761-75. PubMed ID: 24356578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.
    Yang J; Chen YN; Xu ZX; Mou Y; Zheng LR
    Cell Physiol Biochem; 2016; 39(1):229-41. PubMed ID: 27336844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.
    Yang J; Zhu HH; Chen GP; Ye Y; Zhao CZ; Mou Y; Hu SJ
    Int J Biochem Cell Biol; 2013 Mar; 45(3):657-66. PubMed ID: 23277274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro.
    Li Z; Bi X; Wang M; Zhang J; Song J; Shen X; Han J; Fu G; Ye Y
    Clin Exp Immunol; 2014 Jun; 176(3):429-37. PubMed ID: 24527834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.
    Yang Y; Rong X; Lv X; Jiang W; Yang Y; Lai D; Xu S; Fu G
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28665545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced fibrotic responses in vascular smooth muscle cells.
    Du CQ; Liu XW; Zeng GZ; Jin HF; Tang LJ
    Int J Mol Med; 2015 Jun; 35(6):1767-72. PubMed ID: 25847782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of farnesyl pyrophosphate synthase attenuates high glucose‑induced vascular smooth muscle cells proliferation.
    Chen GP; Zhang XQ; Wu T; Han J; Ye D
    Mol Med Rep; 2017 May; 15(5):3153-3160. PubMed ID: 28339090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knock-down of farnesyl pyrophosphate synthase protects heart-derived H9c2 cells against hypoxia/reoxygenation-induced injury.
    Dai D; Wu H; Yang J; Shen S; Zhao C; Ding J; Hu S
    Cell Biol Int; 2017 Sep; 41(9):982-990. PubMed ID: 28544034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.
    Li L; Chen GP; Yang Y; Ye Y; Yao L; Hu SJ
    Biochem Pharmacol; 2010 Feb; 79(3):399-406. PubMed ID: 19800872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.
    Chen A; Li W; Chen X; Shen Y; Dai W; Dong Q; Li X; Ou C; Chen M
    BMC Cardiovasc Disord; 2016 Nov; 16(1):225. PubMed ID: 27855650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FPPS mediates TGF-β1-induced non-small cell lung cancer cell invasion and the EMT process via the RhoA/Rock1 pathway.
    Lin L; Li M; Lin L; Xu X; Jiang G; Wu L
    Biochem Biophys Res Commun; 2018 Feb; 496(2):536-541. PubMed ID: 29337059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat.
    Liu X; Liu Y; Tang L; Du C
    Cell Cycle; 2023; 22(6):666-679. PubMed ID: 36310380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulator of G-Protein Signaling 10 Negatively Regulates Cardiac Remodeling by Blocking Mitogen-Activated Protein Kinase-Extracellular Signal-Regulated Protein Kinase 1/2 Signaling.
    Miao R; Lu Y; Xing X; Li Y; Huang Z; Zhong H; Huang Y; Chen AF; Tang X; Li H; Cai J; Yuan H
    Hypertension; 2016 Jan; 67(1):86-98. PubMed ID: 26573707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of farnesyl pyrophosphate synthase increases myocardial ischemia/reperfusion injury in mice.
    Dai D; Sun X; Ding J; Chen Y; Hu S
    Gene; 2018 Sep; 672():72-78. PubMed ID: 29864496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.
    Ye Y; Mou Y; Bai B; Li L; Chen GP; Hu SJ
    Int J Biochem Cell Biol; 2010 Dec; 42(12):2056-64. PubMed ID: 20884373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload.
    Gravning J; Ahmed MS; von Lueder TG; Edvardsen T; Attramadal H
    Int J Cardiol; 2013 Oct; 168(3):2049-56. PubMed ID: 23452880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
    You J; Wu J; Jiang G; Guo J; Wang S; Li L; Ge J; Zou Y
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):142-51. PubMed ID: 23188126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
    Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.